Skip to content

Samuel J Carter

5 papers in the library · 523 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Deconstruction of lysergic acid diethylamide.

Proceedings of the National Academy of Sciences of the United States of America September 8, 2026 Andrian G Basargin, Andras Domokosa, Joseph J Hennessey et al.

Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in...

Design, Synthesis, and In Vitro Characterization of a Tryptamine-Based Visible-Light Photoswitchable 5-HT2AR Ligand Showing Efficacy Preference for β-Arrestin over Mini-Gq.

Journal of Medicinal Chemistry June 18, 2025 Alexandra Sink, Eline Pottie, Samuel J Carter et al. 2 citations

The serotonin 2A receptor (5-HT2AR) modulates various neurotransmitter systems and is implicated in psychiatric disorders, including depression and schizophrenia. Despite progress, the detailed mechanisms of signaling at the 5-HT2AR and its therapeutic implications remain unclear, warranting further exploration. Overcoming the limitations of conventional pharmacology, photopharmacology...

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

Proceedings of the National Academy of Sciences April 14, 2025 Jeremy R Tuck, Lee E. Dunlap, Yara A Khatib et al. 32 citations

Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and schizophrenia (SCZ). Psychedelics possess a remarkable ability to promote cortical neuron growth and increase spine density; however, these compounds are contraindicated for patients with SCZ or a family history of psychosis. Here, we report the...

Efficient and modular synthesis of ibogaine and related alkaloids.

Nature chemistry March 1, 2025 Rishab N Iyer, David Favela, Andras Domokos et al. 22 citations

Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerful anti-addictive properties, producing long-lasting therapeutic effects across a range of substance use disorders and co-occurring neuropsychiatric diseases such as depression and post-traumatic stress disorder. Here we report a gram-scale,...

Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors

Science February 16, 2023 Maxemiliano V. Vargas, Lee E. Dunlap, Chunyang Dong et al. 467 citations

Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie the rapid and sustained therapeutic effects of psychedelics. Activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT2ARs) is essential for psychedelic-induced cortical plasticity, but it is currently...